Drug Interactions between halothane and lixisenatide
This report displays the potential drug interactions for the following 2 drugs:
- halothane
- lixisenatide
Interactions between your drugs
halothane lixisenatide
Applies to: halothane and lixisenatide
ADJUST DOSING INTERVAL: Treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist or a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist may increase the risk of regurgitation and pulmonary aspiration of gastric contents in patients undergoing general anesthesia due to delayed gastric emptying caused by stimulation of central nervous system GLP-1 receptors and vagal nerve activation. Pulmonary aspiration of regurgitated gastric contents during anesthesia may result in pneumonitis, aspiration pneumonia, other lung injury, and even death. Cases associated with the use of GLP-1 agonists, particularly for the treatment of weight loss, have been documented in the medical literature. There have also been reports of aborted procedures in patients treated with these agents due to the presence of significant residual gastric contents despite adherence to preoperative fasting protocols prior to anesthesia. The effects on gastric emptying may be reduced with long-term use, most likely through rapid tachyphylaxis at the level of vagal nerve activation. Therefore, patients who have recently started treatment with these agents may be at greater risk of delayed gastric emptying and pulmonary aspiration than those who have been taking them for a longer period. Additionally, patients experiencing gastrointestinal (GI) symptoms from these agents, including nausea, vomiting or abdominal distension, have a greater risk of increased residual gastric contents regardless of fasting.
MANAGEMENT: Although data are limited, caution and close monitoring are advisable when general anesthesia or deep sedation is required in patients receiving GLP-1 agonists or dual GIP/GLP-1 agonists. Consideration should be given to withholding these medications prior to the scheduled procedure whenever possible, although the optimal duration of treatment interruption has not been established. The benefits of these medications on glycemic control should also be weighed against the risk of regurgitation and pulmonary aspiration in determining if and for how long these medications should be withheld. For elective procedures, the American Society of Anesthesiologists (ASA) Task Force on Preoperative Fasting suggests pausing the GLP-1 agonist or dual GIP/GLP-1 agonist on the day of the procedure for patients on daily dosing and a week prior to the procedure for patients on weekly dosing. This recommendation is irrespective of the indication (type 2 diabetes mellitus or weight loss) or the type of procedure or surgery. If treatment is suspended for longer than the dosing schedule in patients with diabetes, consult with an endocrinologist on bridging the antidiabetic therapy to avoid hyperglycemia. On the day of the procedure, if GI symptoms such as severe nausea/vomiting/retching, abdominal bloating, or abdominal pain are present, consider delaying elective procedure; otherwise, proceed as usual if the GLP-1 agonist or dual GIP/GLP-1 agonist has been held as advised. If no GI symptoms are present, but the GLP-1 agonist or dual GIP/GLP-1 agonist was not held as advised, proceed with "full stomach" precautions or consider evaluating gastric volume by ultrasound. Patients whose stomach is empty can proceed as usual. For patients whose stomach is full or gastric ultrasound is inconclusive or not possible, consider delaying the procedure or treat the patient as "full stomach" and manage accordingly. Likewise, patients requiring urgent or emergent procedures should be treated as "full stomach" and managed accordingly. Similar guidelines have been provided by the Canadian Anesthesiologists' Society, the main difference being its recommendation that GLP-1 agonists and dual GIP/GLP-1 agonists be held for 3 half-lives (approximately 88% clearance of the drug) in patients receiving these agents for weight management.
References (8)
- Gariani K, Putzu A (2024) "Glucagon-like peptide-1 receptor agonists in the perioperative period: Implications for the anaesthesiologist." Eur J Anaesthesiol, 41, p. 245-6
- Jones PM, Hobai IA, Murphy PM (2023) "Anesthesia and glucagon-like peptide-1 receptor agonists: proceed with caution!" Can J Anaesth, 70, p. 1281-6
- ASA. American Society of Anesthesiologists (2024) American Society of Anesthesiologists Consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-soci
- ISMP Canada. Institute for Safe Medication Practices Canada (2024) Glucagon-like peptide-1 (GLP-1) receptor agonists: risk of aspiration during anesthesia. https://ismpcanada.ca/wp-content/uploads/ISMPCSB2023-i9-GLP-1.pdf
- Klein SR, Hobai IA (2023) "Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report." Can J Anaesth, 70, p. 1394-6
- Fujino E, Cobb KW, Schoenherr J, Gouker L, Lund E (2024) Anesthesia considerations for a patient on semaglutide and delayed gastric emptying https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438952/pdf/cureus-0015-00000042153.pdf
- Gulak MA, Murphy P (2023) "Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report." Can J Anaesth, 70, p. 1397-400
- Queiroz VNF, Falsarella PM, Chaves RCF, Takaoka F, Socolowski LR, Garcia RG (2024) Risk of pulmonary aspiration during semaglutide use and anesthesia in a fasting patient: a case report with tomographic evidence. https://www.scielo.br/j/eins/a/vh5QhcmddxTjJxh9C6vk5HN/?format=pdf&lang=en
Drug and food interactions
lixisenatide food
Applies to: lixisenatide
ADJUST DOSING INTERVAL: Lixisenatide slows gastric emptying, which may impact the absorption of concomitantly administered oral medications. The interaction has been studied with various medications, which demonstrated primarily an effect on the rate rather than the overall extent of absorption.
Acetaminophen: When acetaminophen 1000 mg was administered 1 hour and 4 hours after lixisenatide 10 mcg injection, acetaminophen peak plasma concentration (Cmax) was decreased by 29% and 31%, respectively; and median time to peak plasma concentration (Tmax) was delayed by 2 hours and 1.75 hours, respectively. The Cmax and Tmax of acetaminophen were not significantly altered when acetaminophen was given one hour before lixisenatide injection, and systemic exposure (AUC) was not affected whether administered before or after lixisenatide administration. Based on these results, no dose adjustment for acetaminophen is required; however, it may be advisable to take acetaminophen at least one hour before lixisenatide if a rapid onset of action is required.
Oral Contraceptives: When an oral contraceptive containing ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg was administered 1 hour and 4 hours after lixisenatide 10 mcg injection, ethinyl estradiol Cmax was decreased by 52% and 39%, respectively, while levonorgestrel Cmax was decreased by 46% and 20%, respectively. Median Tmax values were delayed by 1 to 3 hours, but overall exposure (AUC) and mean terminal half-life (T1/2) of ethinyl estradiol and levonorgestrel were not significantly altered. Administration of the oral contraceptive 1 hour before or 11 hours after lixisenatide had no effect on any of the measured pharmacokinetic parameters of either ethinyl estradiol or levonorgestrel. Based on these results, no dose adjustment for oral contraceptives is required; however, some authorities recommend that oral contraceptives be administered at least 1 hour before or 11 hours after lixisenatide.
Atorvastatin: When atorvastatin 40 mg and lixisenatide 20 mcg were coadministered in the morning for 6 days, atorvastatin Cmax was decreased by 31% and Tmax was delayed by 3.25 hours, but AUC was not affected. When atorvastatin was administered in the evening and lixisenatide in the morning, the AUC and Cmax of atorvastatin were increased by 27% and 66%, respectively, but there was no change in Tmax. Based on these results, no dose adjustment for atorvastatin is required; however, some authorities recommend that atorvastatin be administered at least 1 hour before lixisenatide.
Warfarin: When warfarin 25 mg was coadministered with repeated dosing of lixisenatide 20 mcg, warfarin Cmax was decreased by 19% and Tmax was delayed by 7 hours, but there were no effects on AUC or International Normalized Ratio (INR). Based on these results, no dose adjustment for warfarin is required; however, closer monitoring of INR may be appropriate following initiation or discontinuation of lixisenatide treatment.
Digoxin: When digoxin 0.25 mg and lixisenatide 20 mcg were coadministered at steady state, digoxin Cmax was decreased by 26% and Tmax was delayed by 1.5 hours, but AUC was not affected. Based on these results, no dose adjustment for digoxin is required.
Ramipril: When ramipril 5 mg and lixisenatide 20 mcg were coadministered for 6 days, ramipril Cmax was decreased by 63% and AUC was increased by 21%, while Cmax and AUC of the active metabolite (ramiprilat) were not affected. The Tmax values of ramipril and ramiprilat were delayed by approximately 2.5 hours. Based on these results, no dose adjustment for ramipril is required.
MANAGEMENT: Caution is advised during concomitant use of lixisenatide with oral medications that have a narrow therapeutic index or that require careful clinical monitoring. These medications should be administered on a consistent schedule relative to lixisenatide, and blood levels and/or pharmacologic effects should be closely monitored. In addition, if they are to be administered with food, patients should be advised to take them with a meal or snack when lixisenatide is not administered. Oral medications that are particularly dependent on threshold concentrations for efficacy, such as antibiotics, or medications for which a delay in effect is undesirable, such as acetaminophen, should be administered at least 1 hour before lixisenatide. Gastro-resistant formulations containing substances sensitive to stomach degradation should be administered 1 hour before or 4 hours after lixisenatide. Patients taking oral contraceptives should be advised to take them at least 1 hour before or 11 hours after lixisenatide.
References (1)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.